OncoMatch/Clinical Trials/NCT06964737
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Is NCT06964737 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Anti-GARP Chimeric Antigen Receptor-T Cells for recurrent malignant glioma.
Treatment: Anti-GARP Chimeric Antigen Receptor-T Cells — This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Disease stage
Required: Stage III, IV (WHO)
measurable disease by the Radiologic Assessment in Neuro-Oncology (RANO) criteria
Prior therapy
Cannot have received: VEGF inhibitor (bevacizumab)
Subjects must not have received bevacizumab therapy and are not planned to start such therapy
Cannot have received: chemotherapy (temozolomide)
Exception: must stop treatment 14 days prior to undergoing apheresis and remain off therapy throughout the duration of CAR T therapeutic intervention
Patients receiving anti-cancer agents such as chemotherapy (e.g., temozolomide) must stop treatment 14 days prior to undergoing apheresis and remain off therapy throughout the duration of CAR T therapeutic intervention
Lab requirements
Blood counts
white blood cells (wbc) > 4,000 cells/ul; hemoglobin (hgb) > 7 gm/dl; platelets (plt) > 100/dl
Kidney function
serum creatinine ≤ 1.5 x institutional upper limit of normal
Liver function
liver function tests within 1.5 x institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06964737 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGF inhibitor, chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages